Randomized controlled trial results published in the International Journal of Tissue Repair demonstrate BioRetain® allografts significantly improve probability of achieving lasting wound closure versus standard of carePOMPANO BEACH, Fla., Oct. 31, 2025 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (“BioStem” or the “Company”) (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care, today announced top-line ...

Company Overview - BioStem Technologies is a profitable med tech company focused on advanced wound care [2] - The company's core technology is BioREtain, which processes placental-based tissue allografts for advanced wound care [2][3] Market Potential - The target patient population includes approximately 7 million Medicare beneficiaries [3] - The total market for advanced wound care is estimated to be around $11.3 billion [3]